Charmacy Pharmaceutical Declares Final 2025 Dividend of RMB 0.3 per Share

The latest update is out from Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ).

Charmacy Pharmaceutical Co., Ltd. has declared a final ordinary cash dividend of RMB 0.3 per share for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 22 May 2026. Key details for Hong Kong shareholders, including the Hong Kong dollar equivalent, exchange rate, ex-dividend date, record date, payment date, and applicable withholding tax arrangements, will be announced later, signaling an upcoming cash return to investors while leaving the precise timetable and local currency payout still to be clarified.

The dividend declaration underlines the company’s intention to reward shareholders for the 2025 financial year and may reflect management’s confidence in its financial performance and cash position. However, the absence of finalized logistical details around the dividend distribution means investors must wait for further disclosures to fully assess the timing and net amount of the payout, which could influence near-term trading and income expectations for holders of the company’s H-shares.

The most recent analyst rating on (HK:2289) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Charmacy Pharmaceutical Co., Ltd. Class H stock, see the HK:2289 Stock Forecast page.

More about Charmacy Pharmaceutical Co., Ltd. Class H

Charmacy Pharmaceutical Co., Ltd. is a Hong Kong–listed pharmaceutical company operating in the healthcare sector, focusing on the manufacture and distribution of pharmaceutical products. Its shares trade under stock code 02289, and it serves investors through the Hong Kong market with ordinary share capital subject to standard dividend arrangements.

Average Trading Volume: 10,700

Technical Sentiment Signal: Sell

Current Market Cap: HK$627.5M

Learn more about 2289 stock on TipRanks’ Stock Analysis page.